<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003224</url>
  </required_header>
  <id_info>
    <org_study_id>6346</org_study_id>
    <secondary_id>NCI-H98-0010</secondary_id>
    <nct_id>NCT00003224</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With a Synthetic Melanoma Peptide in Patients With High Risk Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptide 946 may make the body build an immune response to kill
      tumor cells. Combining these vaccines with proteins from the tetanus vaccine, and/or with
      either QS21 or Montanide ISA-51 may be an effective treatment for metastatic melanoma.

      PURPOSE: Randomized phase I trial to study the effectiveness of vaccines made from peptide
      946 with or without tetanus peptide, QS21, or Montanide ISA-51 in treating patients with
      metastatic melanoma that cannot be surgically removed or with melanoma that is likely to
      recur.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Determine the safety of peptide 946 melanoma vaccine (peptide 946), peptide 946 combined
      with tetanus peptide melanoma vaccine, or peptide 946-tetanus peptide conjugate in patients
      with high risk melanoma.

      II. Determine the immunogenicity of peptide 946 melanoma vaccine (peptide 946), peptide 946
      combined with tetanus peptide melanoma vaccine, or peptide 946-tetanus peptide conjugate in
      patients with high risk melanoma.

      OUTLINE: This is a randomized, open-label study. Patients are randomized to 1 of 6 treatment
      arms: Arm I: Patients receive peptide 946 melanoma vaccine (peptide 946) emulsified with QS21
      subcutaneously (SQ). Arm II: Patients receive peptide 946 emulsified with Montanide ISA-51
      (ISA-51) SQ. Arm III: Patients receive peptide 946 combined with tetanus peptide melanoma
      vaccine (tetanus peptide) emulsified with QS21 SQ. Arm IV: Patients receive peptide 946
      combined with tetanus peptide emulsified with ISA-51 SQ. Arm V: Patients receive peptide
      946-tetanus peptide conjugate emulsified with QS21 SQ. Arm VI: Patients receive peptide
      946-tetanus peptide conjugate emulsified with ISA-51 SQ. Initially, 4 patients are randomized
      to Arm I and 4 patients are randomized to Arm II. If no dose limiting toxicities are observed
      in these patients, then additional patients are randomized to arms III-VI. Patients in each
      arm receive vaccine on day 0 and at months 1, 2, 3, 6, 9, and 12. Patients are followed at 6
      and 12 months.

      PROJECTED ACCRUAL: A maximum of 36 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1996</start_date>
  <primary_completion_date type="Actual">August 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Grade 3 Adverse Events</measure>
    <time_frame>Up to 24 months after last vaccine</time_frame>
    <description>Adverse events are monitored according to NCI/DCT Common Toxicity Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Each Vaccine Regimen</measure>
    <time_frame>up to 12 months since enrollment</time_frame>
    <description>T cell responses to the p946 (gp100 [280-288]) peptide. All enrolled patients were assayed for immune response to the gp100 peptide by ELIspot assay after 14 days in vitro sensitization. The number with a response in each study arm is reported.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With a Proliferative Response to Tetanus Helper Peptide</measure>
    <time_frame>during vaccination</time_frame>
    <description>Proliferative response measured in participants using a tritiated thymidine incorporation assay with peripheral blood mononuclear cells (PBMC) stimulated with the tetanus peptide in vitro, and measured at 5 days after in vitro culture.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Group 1: peptide 946 plus QS-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg peptide gp100 [280-288] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2. p946 plus IFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg peptide gp100 [280-288] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: p946 plus Tet-p plus QS-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg peptide gp100 [280-288],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4. p946, Tet-p plus IFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg peptide gp100 [280-288], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: p946/Tet-p plus QS-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6. p946/Tet-p plus IFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QS21</intervention_name>
    <description>vaccine adjuvant</description>
    <arm_group_label>Group 1: peptide 946 plus QS-21</arm_group_label>
    <arm_group_label>Group 3: p946 plus Tet-p plus QS-21</arm_group_label>
    <arm_group_label>Group 5: p946/Tet-p plus QS-21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFA (incomplete Freund's adjuvant)</intervention_name>
    <description>Peptides emulsified in IFA.</description>
    <arm_group_label>Group 2. p946 plus IFA</arm_group_label>
    <arm_group_label>Group 4. p946, Tet-p plus IFA</arm_group_label>
    <arm_group_label>Group 6. p946/Tet-p plus IFA</arm_group_label>
    <other_name>Montanide ISA-51, from Seppic.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>p946</intervention_name>
    <description>This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.</description>
    <arm_group_label>Group 1: peptide 946 plus QS-21</arm_group_label>
    <arm_group_label>Group 2. p946 plus IFA</arm_group_label>
    <arm_group_label>Group 3: p946 plus Tet-p plus QS-21</arm_group_label>
    <arm_group_label>Group 4. p946, Tet-p plus IFA</arm_group_label>
    <other_name>peptide 946, gp100 [280-288], YLEPGPVTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>p946/tet-p</intervention_name>
    <description>This peptide is a longer version of p946 (gp100 [280-288]) sythesized colinearly with the tetanus helper peptide (Tet-p)</description>
    <arm_group_label>Group 5: p946/Tet-p plus QS-21</arm_group_label>
    <arm_group_label>Group 6. p946/Tet-p plus IFA</arm_group_label>
    <other_name>peptide 946-tetanus peptide conjugate melanoma vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tet-p</intervention_name>
    <description>modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.</description>
    <arm_group_label>Group 3: p946 plus Tet-p plus QS-21</arm_group_label>
    <arm_group_label>Group 4. p946, Tet-p plus IFA</arm_group_label>
    <other_name>tetanus peptide melanoma vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically confirmed unresectable metastatic melanoma (AJCC stage III or IV) OR
             resected melanoma with high risk of recurrence or mortality (stage IIB and above)

          -  Age: 18 to 79

          -  Performance status: ECOG 0-2

          -  Life expectancy: Greater than 12 months

          -  Hematopoietic: Absolute neutrophil count greater than 1,000/mm3 Platelet count greater
             than 100,000/mm3 Hemoglobin greater than 9 g/dL

          -  Hepatic: AST and ALT no greater than 2.5 times upper limit of normal (ULN) Bilirubin
             no greater than 2.5 times ULN Alkaline phosphatase no greater than 2.5 times ULN

          -  Renal: Creatinine no greater than 1.5 times ULN

        Exclusion criteria:

          -  patients currently receiving cytotoxic chemotherapy or who have received that therapy
             within the preceding 3 months

          -  known or suspected allergies to any component of the treatment vaccine

          -  unresectable tumor llikely to cause symptoms and for which therapy is anticipated
             within 3 months.

          -  receiving acute treatment for seriouis infection within 14 days.

          -  Patients with bulky disease, or with multiple brain metastases, but solitary brain
             metastases treated successfully with surgery or gamma knife may be eligible.

          -  Any of the following with 3 months:

          -  agentes with putative immunomodulating activity (except NSAIDs)

          -  allergy desensitizing injections

          -  other investigational agents

          -  interferons

          -  corticosteroids

          -  any growth factors

          -  prior melanoma vaccinations

          -  pregnancy or the possibility of becoming pregnant on study

          -  medical contraindication or potential problems in complying with the requirements of
             the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L. Slingluff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center, University of Virginia HSC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001 Oct;7(10):3012-24.</citation>
    <PMID>11595689</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2004</study_first_posted>
  <results_first_submitted>January 22, 2013</results_first_submitted>
  <results_first_submitted_qc>November 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2014</results_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
    <mesh_term>QS 21</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>patients were enrolled at the University of Virginia</recruitment_details>
      <pre_assignment_details>no enrolled patients were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Peptide 946 Plus QS-21</title>
          <description>100 mcg peptide gp100 [280-288] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
        </group>
        <group group_id="P2">
          <title>Group 2. p946 Plus IFA</title>
          <description>100 mcg peptide gp100 [280-288] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
        </group>
        <group group_id="P3">
          <title>Group 3: p946 Plus Tet-p Plus QS-21</title>
          <description>100 mcg peptide gp100 [280-288],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
        </group>
        <group group_id="P4">
          <title>Group 4. p946, Tet-p Plus IFA</title>
          <description>100 mcg peptide gp100 [280-288], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
        </group>
        <group group_id="P5">
          <title>Group 5: p946/Tet-p Plus QS-21</title>
          <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
        </group>
        <group group_id="P6">
          <title>Group 6. p946/Tet-p Plus IFA</title>
          <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Peptide 946 Plus QS-21</title>
          <description>100 mcg peptide gp100 [280-288] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
        </group>
        <group group_id="B2">
          <title>Group 2. p946 Plus IFA</title>
          <description>100 mcg peptide gp100 [280-288] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
        </group>
        <group group_id="B3">
          <title>Group 3: p946 Plus Tet-p Plus QS-21</title>
          <description>100 mcg peptide gp100 [280-288],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
        </group>
        <group group_id="B4">
          <title>Group 4. p946, Tet-p Plus IFA</title>
          <description>100 mcg peptide gp100 [280-288], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
        </group>
        <group group_id="B5">
          <title>Group 5: p946/Tet-p Plus QS-21</title>
          <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
        </group>
        <group group_id="B6">
          <title>Group 6. p946/Tet-p Plus IFA</title>
          <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="17.1"/>
                    <measurement group_id="B2" value="59.6" spread="18.6"/>
                    <measurement group_id="B3" value="44.3" spread="16.8"/>
                    <measurement group_id="B4" value="59.5" spread="17.7"/>
                    <measurement group_id="B5" value="51.8" spread="14.9"/>
                    <measurement group_id="B6" value="69.3" spread="7.5"/>
                    <measurement group_id="B7" value="55.6" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Grade 3 Adverse Events</title>
        <description>Adverse events are monitored according to NCI/DCT Common Toxicity Criteria</description>
        <time_frame>Up to 24 months after last vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All QS-21</title>
            <description>The toxicities are grouped for those receiving the vaccine adjuvant QS-21.</description>
          </group>
          <group group_id="O2">
            <title>All Montanide ISA-51</title>
            <description>The toxicities are grouped for those receiving the vaccine adjuvant IFA (Montanide ISA-51).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Grade 3 Adverse Events</title>
          <description>Adverse events are monitored according to NCI/DCT Common Toxicity Criteria</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of Each Vaccine Regimen</title>
        <description>T cell responses to the p946 (gp100 [280-288]) peptide. All enrolled patients were assayed for immune response to the gp100 peptide by ELIspot assay after 14 days in vitro sensitization. The number with a response in each study arm is reported.</description>
        <time_frame>up to 12 months since enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Peptide 946 Plus QS-21</title>
            <description>100 mcg peptide gp100 [280-288] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Group 2. p946 Plus IFA</title>
            <description>100 mcg peptide gp100 [280-288] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
          </group>
          <group group_id="O3">
            <title>Group 3: p946 Plus Tet-p Plus QS-21</title>
            <description>100 mcg peptide gp100 [280-288],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
          </group>
          <group group_id="O4">
            <title>Group 4. p946, Tet-p Plus IFA</title>
            <description>100 mcg peptide gp100 [280-288], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
          </group>
          <group group_id="O5">
            <title>Group 5: p946/Tet-p Plus QS-21</title>
            <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
          </group>
          <group group_id="O6">
            <title>Group 6. p946/Tet-p Plus IFA</title>
            <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of Each Vaccine Regimen</title>
          <description>T cell responses to the p946 (gp100 [280-288]) peptide. All enrolled patients were assayed for immune response to the gp100 peptide by ELIspot assay after 14 days in vitro sensitization. The number with a response in each study arm is reported.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With a Proliferative Response to Tetanus Helper Peptide</title>
        <description>Proliferative response measured in participants using a tritiated thymidine incorporation assay with peripheral blood mononuclear cells (PBMC) stimulated with the tetanus peptide in vitro, and measured at 5 days after in vitro culture.</description>
        <time_frame>during vaccination</time_frame>
        <population>All evaluable enrolled patients were assayed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Peptide 946 Plus QS-21</title>
            <description>100 mcg peptide gp100 [280-288] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Group 2. p946 Plus IFA</title>
            <description>100 mcg peptide gp100 [280-288] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
          </group>
          <group group_id="O3">
            <title>Group 3: p946 Plus Tet-p Plus QS-21</title>
            <description>100 mcg peptide gp100 [280-288],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
          </group>
          <group group_id="O4">
            <title>Group 4. p946, Tet-p Plus IFA</title>
            <description>100 mcg peptide gp100 [280-288], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
          </group>
          <group group_id="O5">
            <title>Group 5: p946/Tet-p Plus QS-21</title>
            <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant</description>
          </group>
          <group group_id="O6">
            <title>Group 6. p946/Tet-p Plus IFA</title>
            <description>282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Proliferative Response to Tetanus Helper Peptide</title>
          <description>Proliferative response measured in participants using a tritiated thymidine incorporation assay with peripheral blood mononuclear cells (PBMC) stimulated with the tetanus peptide in vitro, and measured at 5 days after in vitro culture.</description>
          <population>All evaluable enrolled patients were assayed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants are reported for adverse events based on vaccine adjuvant received because the adverse events were considered primarily related to the adjuvant. Also, the gp100 peptide was included in all 6 study groups.</desc>
      <group_list>
        <group group_id="E1">
          <title>QS-21 Adjuvant</title>
          <description>The combination of participants from Arms 1, 3, and 5, all treated with peptides plus QS-21 adjuvant</description>
        </group>
        <group group_id="E2">
          <title>Montanide ISA-51 Adjuvant</title>
          <description>The combination of participants from Arms 2, 4, and 6, all treated with peptides plus Montanide ISA-51 adjuvant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophageal spasm, Grade 3</sub_title>
                <description>This occurred in one patient on group 3, whose vaccine incorporated QS-21.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>endocrine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>other gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Other pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>other neurological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>grade 1-2 skin toxicity, especially pain</sub_title>
                <description>vaccine site, typically transient.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>skin, other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Craig Slingluff</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-924-1730</phone>
      <email>cls8h@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

